Effects of drop‐out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia

Hutton P, Morrison AP, Yung AR, Taylor PJ, French P, Dunn G. Effects of drop‐out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.

[1]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[2]  D. Aarsland,et al.  Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway , 2011, Acta psychiatrica Scandinavica.

[3]  A. Bravo-Mehmedbašić.  Risperidone in the treatment of schizophrenia. , 2011, Medicinski arhiv.

[4]  S. Kapur,et al.  The different trajectories of antipsychotic response: antipsychotics versus placebo , 2010, Psychological Medicine.

[5]  M. Jayaram,et al.  Risperidone versus placebo for schizophrenia. , 2010, Schizophrenia bulletin.

[6]  B. Colagiuri.  Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity , 2010, Clinical trials.

[7]  M. Fava,et al.  Assuring that double-blind is blind. , 2010, The American journal of psychiatry.

[8]  B. Bégaud,et al.  Antipsychotic prescribing trends: a review of pharmaco‐epidemiological studies , 2010, Acta psychiatrica Scandinavica.

[9]  J. Moncrieff,et al.  ACTA PSYCHIATRICA , 2006 .

[10]  C. Adams,et al.  Losing participants before the trial ends erodes credibility of findings , 2009 .

[11]  Robert M Hamer,et al.  Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. , 2009, The American journal of psychiatry.

[12]  S. Leucht,et al.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials , 2009, Molecular Psychiatry.

[13]  P. Tyrer,et al.  The spurious advance of antipsychotic drug therapy , 2009, The Lancet.

[14]  John M. Davis,et al.  Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.

[15]  C. McDougle,et al.  Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  C. Mallinckrodt,et al.  The impact of analytic method on interpretation of outcomes in longitudinal clinical trials , 2008, International journal of clinical practice.

[17]  Ian R White,et al.  Imputation methods for missing outcome data in meta-analysis of clinical trials , 2008, Clinical trials.

[18]  J. Lieberman,et al.  Science and recovery in schizophrenia. , 2008, Psychiatric services.

[19]  P. Lane.  Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches , 2008, Pharmaceutical statistics.

[20]  Nicky J Welton,et al.  Allowing for uncertainty due to missing data in meta‐analysis—Part 2: Hierarchical models , 2008, Statistics in medicine.

[21]  Ian R White,et al.  Allowing for uncertainty due to missing data in meta‐analysis—Part 1: Two‐stage methods , 2008, Statistics in medicine.

[22]  O. Gureje,et al.  Questioning an Axiom: Better Prognosis for Schizophrenia in the Developing World? , 2007, Schizophrenia bulletin.

[23]  J. Rabinowitz,et al.  The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. , 2007, Schizophrenia bulletin.

[24]  J. Kane,et al.  Methodological issues in current antipsychotic drug trials. , 2007, Schizophrenia bulletin.

[25]  M. Harrow,et al.  Factors Involved in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications: A 15-Year Multifollow-Up Study , 2007, The Journal of nervous and mental disease.

[26]  David Taylor,et al.  Which antipsychotics would mental health professionals take themselves , 2007 .

[27]  Y. Lecrubier,et al.  The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6‐month double‐blind controlled clinical trial , 2006, Acta psychiatrica Scandinavica.

[28]  Peter C Gøtzsche,et al.  Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review , 2006, BMJ : British Medical Journal.

[29]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[30]  C. Adams,et al.  Aripiprazole for schizophrenia , 2006, British Journal of Psychiatry.

[31]  J. Kane,et al.  Linking the PANSS, BPRS, and CGI: Clinical Implications , 2006, Neuropsychopharmacology.

[32]  S. Potkin,et al.  A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization , 2006, Schizophrenia Research.

[33]  J. Moncrieff,et al.  Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal‐related relapse , 2006, Acta psychiatrica Scandinavica.

[34]  A. Leon,et al.  Attrition in Randomized Controlled Clinical Trials: Methodological Issues in Psychopharmacology , 2006, Biological Psychiatry.

[35]  J. Bola.  Medication-free research in early episode schizophrenia: evidence of long-term harm? , 2006, Schizophrenia bulletin.

[36]  H. Meltzer,et al.  Clozapine alone versus clozapine and risperidone for refractory schizophrenia. , 2006, The New England journal of medicine.

[37]  M. Hummer,et al.  Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. , 2005, Archives of general psychiatry.

[38]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[39]  S. Modell,et al.  Efficacy and safety of lower doses of aripiprazole , 2005 .

[40]  Graham Dunn,et al.  Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods , 2005, Statistical methods in medical research.

[41]  R. Dardennes,et al.  Olanzapine for schizophrenia. , 2005, The Cochrane database of systematic reviews.

[42]  H. Meltzer,et al.  A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. , 2005, The Journal of clinical psychiatry.

[43]  G. Tollefson,et al.  Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial , 1996, Psychopharmacology.

[44]  Shitij Kapur,et al.  How antipsychotics become anti-"psychotic"--from dopamine to salience to psychosis. , 2004, Trends in pharmacological sciences.

[45]  G. Tollefson,et al.  A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse , 2003, Journal of clinical psychopharmacology.

[46]  T. Pigott,et al.  Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. , 2003, The Journal of clinical psychiatry.

[47]  S. Potkin,et al.  Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. , 2003, Archives of general psychiatry.

[48]  B. Soares,et al.  Amisulpride for schizophrenia. , 2002, The Cochrane database of systematic reviews.

[49]  Kenneth F Schulz,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Exclusions before Randomisation Exclusions after Randomisation Sample Size Slippages in Randomised Trials: Exclusions and the Lost and Wayward , 2022 .

[50]  S. Lankappa,et al.  Quetiapine for schizophrenia. , 2004, The Cochrane database of systematic reviews.

[51]  K. Hopper,et al.  Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. International Study of Schizophrenia. , 2000, Schizophrenia bulletin.

[52]  J. Kane,et al.  Controlled, Double-blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo , 1999 .

[53]  Y. Lecrubier,et al.  Olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schizophrenia , 1999, European Neuropsychopharmacology.

[54]  J. Kane,et al.  Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. , 1999, Journal of clinical psychopharmacology.

[55]  A R Jadad,et al.  Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. , 1998, JAMA.

[56]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[57]  S. Satya‐Murti.  Evidence-based Medicine: How to Practice and Teach EBM , 1997 .

[58]  M. Tohen,et al.  Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. , 1997, Archives of general psychiatry.

[59]  L. Fabre,et al.  ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. , 1995, Clinical therapeutics.

[60]  Y. Lecrubier,et al.  Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. , 1995, The American journal of psychiatry.

[61]  S. Fisher,et al.  Suspended judgment. Seeing through the double-masked design: a commentary. , 1994, Controlled clinical trials.

[62]  A Labelle,et al.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. , 1993, Journal of clinical psychopharmacology.

[63]  B. Diamond,et al.  Risperidone: clinical safety and efficacy in schizophrenia. , 1992, Psychopharmacology bulletin.

[64]  A. Korten,et al.  The International Pilot Study of Schizophrenia: five-year follow-up findings , 1992, Psychological Medicine.

[65]  M. Blank,et al.  Social climate of community-based psychiatric treatment facilities and adjustment among persons with schizophrenia , 1989, Schizophrenia Research.